Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28520828.
- Also identified by DOI 10.1001/jamaoncol.2017.1047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted therapies are available? Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life.
Medical subject headings
- Antineoplastic Agents
- Brain Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Protein Kinase Inhibitors